Choroidal Blood Flow Regulation During Isometric Exercise: Effects of Ca2+-Channel Blockade
Information source: Medical University of Vienna
Information obtained from ClinicalTrials.gov on June 20, 2008 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Ocular Physiology; Regional Blood Flow
Intervention: Nifedipine (drug) (Drug)
Phase: Phase 4
Status: Recruiting
Sponsored by: Medical University of Vienna Official(s) and/or principal investigator(s): Gabriele Fuchsjäger-Mayrl, M.D., Principal Investigator, Affiliation: Department of Clinical Pharmacology, Medical University of Vienna
Overall contact: Gerhard Garhöfer, M.D., Phone: +43 1 40400 2981, Email: gerhard.garhoefer@meduniwien.ac.at
Summary
Autoregulation is the ability of a vascular bed to maintain blood flow despite changes in
perfusion pressure. For a long time it had been assumed that the choroid is a strictly
passive vascular bed, which shows no autoregulation. However, recently several groups have
identified some autoregulatory capacity of the human choroid. In the brain and the retina the
mechanism behind autoregulation is most likely linked to changes in transmural pressure. In
this model arterioles change their vascular tone depending on the pressure inside the vessel
and outside the vessel. In the choroid, several observations argue against a direct
involvement of arterioles. In a previous project we were able to identify that the nitric
oxide (NO) – system as well as the endothelin system are involved in choroidal blood flow
regulation during isometric exercise.
In the present study autoregulation of the choroid during isometric exercise will be
investigated and the pressure/flow relationships will be observed in the absence or presence
of a calcium antagonist – nifedipine.
Clinical Details
Official title: Choroidal Blood Flow Regulation During Isometric Exercise: Effects of Ca2+-Channel Blockade
Study design: Treatment, Randomized, Double-Blind, Placebo Control, Crossover Assignment, Safety/Efficacy Study
Primary outcome: Choroidal pressure-blood flow relationship
Eligibility
Minimum age: 19 Years.
Maximum age: 35 Years.
Gender(s): Male.
Criteria:
Inclusion Criteria:
Men aged between 19 and 35 years, nonsmokers
Body mass index between 15th and 85th percentile (Must et al. 1991)
Normal findings in the medical history and physical examination unless the investigator
considers an abnormality to be clinically irrelevant
Normal laboratory values unless the investigator considers an abnormality to be clinically
irrelevant
Normal ophthalmic findings, ametropy more than 3 Dpt.
Exclusion Criteria:
Regular use of medication, abuse of alcoholic beverages, participation in a clinical trial
in the 3 weeks preceding the study
Treatment in the previous 3 weeks with any drug
Symptoms of a clinically relevant illness in the 3 weeks before the first study day
History of hypersensitivity to the trial drug or to drugs with a similar chemical
structure
History or presence of gastrointestinal, liver or kidney disease, or other conditions known
to interfere with, distribution, metabolism or excretion of study drugs
Blood donation during the previous 3 weeks
Locations and Contacts
Gerhard Garhöfer, M.D., Phone: +43 1 40400 2981, Email: gerhard.garhoefer@meduniwien.ac.at
Department of Clinical Pharmacology, Vienna 1090, Austria; Recruiting
Additional Information
Starting date: July 2005
Last updated: January 19, 2006
|